Insight Molecular Diagnostics Inc. Common Stock IMDX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Kitted Products | $0— | $0— | $0— | $24K— | $0— | |
| Laboratory Services | $32K-98.5% | $1.14M-23.4% | $260K+126% | $494K+375% | $2.14M+1,288% | |
| Accounts Receivable Net Current by Product | ||||||
| Kitted Products | $0— | $0— | $0— | $24K— | —— | |
| Laboratory Services | $159K— | $1.1M-31.3% | $261K— | $493K— | —— | |
| Concentration Risk % by Product | ||||||
| Kitted Products | 0%— | —— | 0%— | 5%— | 0%— | |
| Laboratory Services | 100%0.0pp | —— | 100%0.0pp | 95%-5.0pp | 100%— | |
| Non-Current Assets by Geography | ||||||
| Asia Pacific | $36K-74.8% | $63K-62.9% | $89K— | $116K— | $143K— | |
| Europe | $1.72M+23.2% | $1.58M+158% | $1.29M— | $1.36M— | $1.39M— | |
| GB | $407K-20.4% | $433K— | $459K— | $485K— | $511K— | |
| US | $6.75M+32.2% | $7.18M+29.5% | $4.65M— | $4.72M— | $5.11M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insight Molecular Diagnostics Inc. Common Stock break its business down?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) reports revenue by product across 2 parts — Kitted Products and Laboratory Services. Each is extracted from the segment footnotes and tracked over time.
- Where does Insight Molecular Diagnostics Inc. Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insight Molecular Diagnostics Inc. Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
